Sufferers with extreme pancreatic most cancers ache skilled constant enhancements in signs, performance, and world high quality of life following Autonomix’s focused ablation remedy, in keeping with findings shared in a information launch from Autonomix Medical, Inc.
Responding sufferers reported symptom enhancements of roughly 14.5 factors at weeks 4 by six and 26 factors at three months, together with sustained practical positive factors and clinically significant will increase in general high quality of life. People with stage 4 illness, together with these with distant or regional metastases, demonstrated significantly robust responses, with symptom, perform, and world quality-of-life scores all surpassing the edge for significant scientific enchancment.
The corporate famous that these subgroup outcomes complement beforehand reported reductions in ache depth, suggesting that focused nerve ablation could supply multidimensional advantages even in superior illness. Sufferers within the earlier proof-of-concept section skilled speedy ache aid starting at 24 hours post-procedure, sturdy reductions by three months, and excessive charges of opioid discontinuation, which corresponded with enhancements throughout quality-of-life domains. Autonomix acknowledged that these insights will information affected person choice and scientific design for its upcoming U.S. multicenter trial deliberate for 2026.
“These subgroup findings present deeper perception into how and why our ablation strategy is enhancing outcomes throughout diverse affected person varieties,” mentioned Brad Hauser, president and CEO of Autonomix. “The truth that sufferers with late-stage and metastatic illness achieved massive, sturdy enhancements in signs, perform, and world high quality of life underscores the broad applicability and real-world affect of our remedy. Whereas this can be a retrospective post-hoc evaluation with modest affected person numbers that can require potential validation, it can inform our future work in our bigger, multicenter U.S. scientific trials.”
High quality-of-Life Positive factors Noticed Throughout A number of Subgroups
The subgroup evaluation evaluated symptom burden, practical standing, and world high quality of life at a number of timepoints following transvascular ablation: 24 hours, seven days, 4 to 6 weeks, and three months post-procedure. Purposeful scores elevated by 8.15 and 25.56 factors, and world quality-of-life measures improved by 8.33 and 18.06 factors at these respective timepoints.
Sufferers with stage 4 pancreatic most cancers, together with these with distant or regional metastases, skilled a 32.48-point enchancment in signs and an 11.85-point practical improve at weeks 4 to 6. Positive factors remained sturdy at 3 months, and world quality-of-life scores improved by 19.44 factors weeks 4 to 6 weeks and 25 factors at 3 months. All enhancements exceeded clinically significant thresholds.
Ache Aid, Opioid Discontinuation and Security Outcomes
The subgroup evaluation supported prior findings from the proof-of-concept research demonstrating speedy and sustained ache discount. Notable outcomes beforehand reported included statistically vital ache aid inside 24 hours and constant advantages at 7 days, 4 to 6 weeks, and three months. Responding sufferers noticed imply VAS ache reductions of 53.3%, 59.2% and 65.6% at these respective intervals.
Opioid discontinuation mirrored these positive factors. All responding sufferers stopped opioid use by seven days, 73% remained opioid-free at weeks 4 to 6, and all responding sufferers had been opioid-free at three months. Sufferers additionally reported improved high quality of life throughout end-stage illness, and the process demonstrated a powerful security profile all through the commentary interval.
Examine Design, Targets and Subsequent Steps for Autonomix
The PoC 1 research enrolled 20 sufferers with extreme belly ache from unresectable pancreatic most cancers and a minimal life expectancy of three months. The first purpose was to judge the success price of ablating nerves related to cancer-related ache utilizing a transvascular RF ablation strategy. Secondary targets included assessing procedure-related adversarial occasions, modifications in ache depth, and modifications in high quality of life throughout outlined timepoints. All sufferers with a profitable process had been assessed at 7 days, 4 to 6 weeks, and three months.
Autonomix has since launched an up to date design to broaden the remedy’s potential attain by exploring functions in further visceral cancers that transmit ache by the celiac plexus, in addition to earlier-stage pancreatic cancers with average to extreme ache. This section will give attention to interventional most cancers ache administration for pancreatic, gallbladder, liver and bile duct cancers, with alternatives for future enlargement into different scientific areas supported by rising preclinical knowledge.
The corporate expects insights from the subgroup evaluation to tell its upcoming multicenter U.S. scientific trial deliberate to start in 2026.
Reference
- “Autonomix Medical, Inc. Studies Constructive Subgroup Outcomes Demonstrating Sustained Enhancements in High quality of Life from Put up Hoc Evaluation of Pancreatic Most cancers PoC Examine,” by Autonomix Medical, Inc. Information launch; Nov. 17, 2025.
For extra information on most cancers updates, analysis and schooling,
